Difference between revisions of "Giant-cell tumor of bone"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 75%; text-align:center;"" to "{| class="wikitable" style="width: 60%; text-align:center;"") |
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
||
Line 29: | Line 29: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010 (Amgen 20040215)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010 (Amgen 20040215)] | ||
|2006-2008 | |2006-2008 | ||
− | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2 (RT) |
|- | |- | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70277-8/fulltext Chawla et al. 2013 (Amgen 20062004)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70277-8/fulltext Chawla et al. 2013 (Amgen 20062004)] | ||
|2008-2011 | |2008-2011 | ||
− | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2 (RT) |
|- | |- | ||
|} | |} |
Revision as of 17:59, 12 February 2022
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ![]() |
1 regimens on this page
1 variants on this page
|
All lines of therapy
Denosumab monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Thomas et. al 2010 (Amgen 20040215) | 2006-2008 | Phase 2 (RT) |
Chawla et al. 2013 (Amgen 20062004) | 2008-2011 | Phase 2 (RT) |
Targeted therapy
- Denosumab (Xgeva) as follows:
- Cycle 1: 120 mg SC once per day on days 1, 8, 15
- Cycle 2 onwards: 120 mg SC once on day 1
Supportive medications
- Calcium 500 mg PO once per day
- Vitamin D 400 IU PO once per day
28-day cycles
References
- Amgen 20040215: Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. Epub 2010 Feb 10. link to original article contains verified protocol PubMed NCT00396279
- Amgen 20062004: Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. link to original article contains protocol PubMed NCT00680992
- Update: Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. link to original article PubMed